Agios Pharmaceuticals, Inc. - Common Stock, Par Value $0.001 per share (AGIO)

CUSIP: 00847X104

Q4 2025 13F Holders as of 31 Dec 2025

Holder snapshot 7 signals
Share change
-4,079,354
Put/Call ratio
32%
SEC-reported price per share
$27.22
Number of holders
237
Value change
-$303,649,463
Number of buys
135
Open additional details 1 more signal available
Number of sells
114
Security identity Names, identifiers, and filing context for this profile. 1 source field
Shares outstanding
59,829,338

Security key

00847X104

Report period

Q4 2025

Institutions

237

Top holders

10

Ownership snapshot

Top reported holders of AGIO - Agios Pharmaceuticals, Inc. - Common Stock, Par Value $0.001 per share (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.

Comparable stake leader
Farallon Capital Partners...
Disclosed value leader
FARALLON CAPITAL MANAGEME...
Comparable rows
4/15
Latest evidence
31 Dec 2025
13D/G 13F Lead comparable stake: 8.8% 11 rows are not safely comparable across share classes. 13D/G row: Farallon Capital Partners, L.P. Showing 1-6 of 15 holder rows.

Quick read

Farallon Capital Partners, L.P. leads the comparable SEC ownership view at 8.8%.

4 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.

Open SEC evidence Opens Farallon Capital Partners, L.P.'s linked filing trail.
Comparable ownership Top 4
Farallon Capital Partners, L.P. 8.8%
BlackRock, Inc. 7.8%
STATE STREET CORP 5.3%
Paradigm Biocapital Advisors LP 4.9%

Ownership % is shown only when SEC disclosures are safely comparable across share classes.

Detailed SEC evidence table Showing 1-6 of 15 holder rows
Holder Evidence Ownership % Position 12M Net Δ As of
Farallon Capital Partners, L.P.
13D/G
Dapice Joshua J.
8.8%
Reported 13D/G · 31 Dec 2025
$146,117,182
5,159,505 shares
-$14,583,696 31 Dec 2025
BlackRock, Inc.
13F 13D/G
Company
7.8%
Reported 13D/G · 30 Jun 2025
$182,465,924
4,545,738 shares
— 30 Sep 2025
STATE STREET CORP
13F 13D/G
Company · STATE STREET CORPORATION
5.3%
Reported 13D/G · 31 Dec 2025
$90,825,260
2,262,712 shares
— 30 Sep 2025
Paradigm Biocapital Advisors LP
13D/G 13F
Company
4.9%
Reported 13D/G · 30 Sep 2025
$115,344,498
2,873,555 shares
-$6,198,499 30 Sep 2025
FARALLON CAPITAL MANAGEMENT, L.L.C.
13F
Company
13F
—
denominator unverified
$232,051,989
5,781,066 shares
— 30 Sep 2025
VANGUARD GROUP INC
13F
Company
13F
—
denominator unverified
$224,979,722
5,604,876 shares
— 30 Sep 2025
How to read this table

Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

13F holder rows

Institutional holders as of Q4 2025

Investor-level positions for this CUSIP, loaded as an interactive table.

Institutions
237
Shares
61,265,073
Rows available
237
Investor Option Weight % Change % SEC-reported value * Price Shares Share Change Activity Report Period

* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.

Compare Q4 2025 vs Q3 2025 Across Filers

Q3 2025 holders
216
Q4 2025 holders
237
Holder diff
21
Investor Q3 2025 Shares Q4 2025 Shares Share Diff Share Chg % Q3 2025 value Q4 2025 value Value change Value Chg %
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .